Complete remission of philadelphia chromosome-positive acute myeloid leukemia with imatinib mesylate / 대한내과학회지
Korean Journal of Medicine
; : 132-137, 2010.
Article
en En
| WPRIM
| ID: wpr-86562
Biblioteca responsable:
WPRO
ABSTRACT
Philadelphia chromosome-positive acute myeloid leukemia (Ph+AML) is a rare disease characterized by a poor prognosis with resistance to standard chemotherapy. We report a patient with Ph+AML with a minor BCR-ABL-positive mRNA transcript who achieved a hematologic, cytogenetic, and major molecular complete response after cytarabine-based chemotherapy followed by imatinib. After more than 6 months of continuous imatinib therapy, the patient is in continuous complete remission. Our results show that imatinib mesylate is effective in treating Ph+AML.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Piperazinas
/
Pronóstico
/
Pirimidinas
/
Benzamidas
/
Cromosoma Filadelfia
/
ARN Mensajero
/
Leucemia Mieloide Aguda
/
Leucemia
/
Philadelphia
/
Mesilatos
Tipo de estudio:
Prognostic_studies
Límite:
Humans
País/Región como asunto:
America do norte
Idioma:
En
Revista:
Korean Journal of Medicine
Año:
2010
Tipo del documento:
Article